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Periodic Fever in MVK Deﬁciency: A Patient Initially
Diagnosed With Incomplete Kawasaki Disease
abstract
Mevalonate kinase deﬁciency (MKD) is a rare autosomal recessive dis-
order causing 1 of 2 phenotypes, hyperimmunoglobulin D syndrome
and mevalonic aciduria, presenting with recurrent fever episodes, often
starting in infancy, and sometimes evoked by stress or vaccinations.
This autoinﬂammatory disease is caused by mutations encoding the
mevalonate kinase (MVK) gene and is classiﬁed in the group of periodic
fever syndromes. There is often a considerable delay in the diagnosis
among pediatric patients with recurrent episodes of fever. We present
a case of an 8-week-old girl with fever of unknown origin and a marked
systemic inﬂammatory response. After excluding infections, a tentative
diagnosis of incomplete Kawasaki syndrome was made, based on the
ﬁnding of dilated coronary arteries on cardiac ultrasound and fever,
and she was treated accordingly. However, the episodes of fever re-
curred, and alternative diagnoses were considered, which eventually
led to the ﬁnding of increased excretion of mevalonic acid in urine. The
diagnosis of MKD was conﬁrmed by mutation analysis of the MVK gene.
This case shows that the initial presentation of MKD can be indistin-
guishable from incomplete Kawasaki syndrome. When fever recurs in
Kawasaki syndrome, other (auto-)inﬂammatory diseases must be ruled
out to avoid inappropriate diagnostic procedures, ineffective interven-
tions, and treatment delay. Pediatrics 2014;133:e461–e465
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Mevalonate kinase deﬁciency (MKD) is
anautosomalrecessivediseaseresulting
from mutations in the MVK gene, which
encodes the enzyme mevalonate kinase
(MVK). This enzyme is involved in the
synthesis of isoprenoids and cholesterol,
and mutations in the gene are the un-
derlying cause of both the milder phe-
notype known as hyperimmunoglobulin
D syndrome (HIDS; OMIM #260920) and
the more severe phenotype, mevalonic
aciduria (OMIM #610377).1–3 HIDS is 1 of
the hereditary autoinﬂammatory syn-
dromes, characterized by inﬂammatory
attacks generally starting in infancy with
fever as the primary symptom. In HIDS,
symptoms typically start at amedian age
of 6 months, and patients experience
repeated febrile attacks into adulthood.
In childhood, the febrile attacks usually
occur every 4 to 6 weeks, but as the
patients grow older, the intervals be-
tween attacks tend to be prolonged.4
Fever can be accompanied by a variety of
symptoms such as lymphadenopathy,
skin lesions, arthralgia, and arthritis, as
well as abdominal pain and diarrhea.4–6
In patients with HIDS, the fever attacks
typically last 3 to 6 days and can be
provoked by vaccinations,minor trauma,
or emotional stress. Sporadically, epi-
sodes can last longer, even up to several
weeks. Incidentally, oral or vaginal ulcers
are reported.7 In general, a strong acute-
phase response is seenwith signiﬁcantly
elevated C-reactive protein, sometimes
combined with elevated levels of
interleukin-1, interleukin-6, and tumor
necrosis factor in serum.4,8
Infants and young children with fever of
unknown origin are frequently referred
to hospitals for diagnostic evaluation.
The differential diagnosis is broad, and
the diagnosis of MKD can be challeng-
ing. Diagnosis of MKD is therefore often
delayed, with some series reporting
a median delay of up to 10 years.9 In
children, an elevated level of serum
immunoglobulin D (IgD) is neither
sensitive nor speciﬁc for the diagnosis
of MKD.3,4 The diagnosis of MKD can be
conﬁrmed by measuring increased
excretion of mevalonic acid reﬂecting
the reduced activity of theMVK enzyme1–4
and by the ﬁnding of mutations in the
MVK gene. Many mutations have been
recognized, 4 of which are responsible
for .70% of all cases.1,2 These gene
mutations result in an 85% to 95% re-
duction of MVK enzyme activity.
We report a case of a young female
patient admitted to our hospital for
evaluation of fever of unknown origin.
She was initially diagnosed and treated
for incomplete Kawasaki syndrome, but
at a later stage, after recurrence of
fever attacks, it turned out that the
correct diagnosis was HIDS.
CASE REPORT
An 8-week-old white girl, ﬁrst child of
non-consanguineous parents of Dutch
origin with an unremarkable medical
history, presented at our hospital with
fever for a total of 6 dayswithout a clear
origin. Fever persisted despite admin-
istration of broad-spectrum antibiotics
(amoxicillin + clavulanic acid and gen-
tamicin). The fever was accompanied
withsignsofmildpurulent conjunctivitis
and redness around the umbilical area,
resembling omphalitis, and she seemed
to develop subtle changes in conscious-
ness during fever peaks, which led to
referral to our hospital. The child had
not yet had the ﬁrst immunizationwhen
the fever commenced.
Physical examination on admission re-
vealed an irritable infant with a tem-
perature of 38.8°C. Other ﬁndings were
a purulent conjunctivitis and redness
surrounding the umbilical area. There
was desquamation of the lips and a
slightly enlarged liver. A grade 2/6
cardiac murmur was detected through
auscultation of the heart. There were
no remarkable changes in the extrem-
ities or skin, and no apparent lymph-
adenopathy. Laboratory evaluation
showed strongly elevated inﬂammatory
parameters (C-reactive protein: 252
mg/L; erythrocyte sedimentation rate:
.140 mm/h), anemia (hemoglobin: 4.4
mmol/L or 6.6 mg/dL), and an elevated
leukocyte count (23.7 3 109/L) with
a predominance of neutrophils and
thrombocytes of 543 3 109/L. Serum
transaminases, creatinine, ferritin,
and standard coagulation test results
were normal. Using culture, poly-
merase chain reaction, and serology
samples, no evidence of viral or bac-
terial infections were found in blood,
cerebrospinal ﬂuid, or urine.
Because of the persistent unexplained
fever with evidence of severe systemic
inﬂammation, treatment of incomplete
Kawasaki syndrome was initiated ac-
cording to international guidelines with
intravenous immunoglobulin (IVIg; 2 g/kg
in 24 hours) and acetylsalicylic acid (80
mg/kg daily)10 while awaiting cardiac
ultrasound. Cardiac ultrasound per-
formed on the fourth day of admission
(day 10 after the onset of fever) revealed
mild dilation of the right (maximum di-
ameter: 2.0 mm; z score: 2.6) (Fig 1) and
left (maximum diameter: 2.1 mm;
z score: 2.2) coronary artery.
Initially, 36hoursaftercompletionof the
IVIg, the fever resolved and there were
clear signs of clinical recovery. How-
ever, 2 days later, the fever reappeared
and a second dose of IVIg was given
while thepatientwasstill onahighdose
of acetylsalicylic acid. She again re-
sponded well, with normalization of in-
ﬂammatory parameters, and the fever
subsided. She was discharged in good
clinical condition. During follow-up, a
repeat ultrasound of the heart was
performedshowingnormalization of the
z score of the coronary arteries; this
ﬁnding was conﬁrmed a few months
later (Table 1).
Six weeks after discharge, the patient
again developed a fever, this time after
vaccination against diphtheria-tetanus-
pertussis-poliomyelitis, Haemophilus
inﬂuenzae, and pneumococci. In the
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subsequent months, she continued to
present regularly with episodes of fe-
ver accompanied by various symptoms
such as bloody diarrhea, malaise, and
erythematous skin lesions. The occa-
sional bloody stools were judged to be
a part of an inﬂammatory response or
nonsteroidal antiinﬂammatory drug
(NSAID) treatment, and no colonoscopy
was performed. Interestingly, at car-
diologic follow-up, the dilation of the
proximal coronary arteries had spon-
taneously resolved within 5 months
after the initial presentation. Episodes
of fever persisted, characterized by
abdominal pain and fatigue, recurring
every 4 to 6 weeks and lasting for 3 to 5
days. This ﬁnding led to the suspicion of
a periodic fever syndrome such as
cryopyrin-associated periodic syndrome
or MKD, warranting further inves-
tigations. The urinary mevalonic acid
excretion was strongly elevated (13.1
mmol/mmol creatinine [normal: ,0.8
mmol/mmol creatinine]) as was plasma
mevalonic acid (1.12 mmol/L [normal:
,0.034 mmol/L]). Mutation analysis of
the MVK gene revealed that the girl was
compound heterozygote for 2mutations,
c.803T.C (p.Ile268Thr) and c.1129G.A
(p.Val377Ile), known to be associated
with the HIDS phenotype. Genotyping of
both parents revealed that both parents
carried a heterozygous mutation of the
MVK gene: mother, c.803T.C (p.Ile268Thr);
father, c.1129G.A (p.Val377Ile).
Thepatientwas initially treated forHIDS
by using supportive therapy, NSAIDs,
and acetaminophen, but because of
frequent episodes of fever in combi-
nation with debilitating symptoms of
severe fatigue and discomfort during
the fever episodes, we started treat-
ment with a recombinant interleukin-1
receptorantagonist (anakinra [Kineret,
Swedish Orphan Biovitrum, Stockholm,
Sweden]) in a prophylactic regimen.
Unfortunately, this regimen did not
signiﬁcantly affect the severity or the
frequency of the feverattacks. Anakinra
wasstoppedwithin12weeks. A6-month
period of prophylactic treatment with
anti–tumor necrosis factor (etanercept)
did not result in less frequent or less se-
vere attacks. Therefore, she was switched
again to treatment with NSAIDs and
acetaminophen. The child has had no
considerable infectious episodes since
the ﬁrst admission.
DISCUSSION
Diagnosing periodic fever syndromes
such as HIDS can be a challenge for
physicians because of the rarity of the
disorders and the considerable overlap
with other inﬂammatory syndromes
andcommon infections. Thisdifﬁculty is
underlinedby the fact that considerable
delay exists before the diagnosis is
made, as was shown in a retrospective
analysis of 103 patients with conﬁrmed
HIDS.9
Kawasaki syndrome is a well-known
entity in young children. The hallmark
of this disease is prolonged fever
without localizing signs as seen in HIDS,
as well as the presence of clear-cut
diagnostic symptoms that serve as di-
agnostic criteria. However, someof these
symptoms, including rash, lymphade-
nopathy, and mucosal changes, also oc-
cur in HIDS. Moreover, in a minority of
patients with Kawasaki syndrome, es-
pecially infants,11 not all principal crite-
ria are Kawasaki syndrome are at risk
for coronary artery complications.12 To
decrease the risk of cardiac or coronary
complications, patients with Kawasaki
disease should receive IVIg and high-
dose met. Moreover, in a minority of
patients with Kawasaki syndrome, es-
pecially infants,11 not all principal crite-
ria are met. Patients with Kawasaki are
at risk for coronary artery complica-
tions.12 To decrease the risk of cardiac
or coronary complications, patientswith
FIGURE 1
Echocardiograph of the patient showing the dilated right coronary artery measuring a maximum of
2.6 mm (average of 2.0 mm) and a z score of 2.6 based on international standards.24,25
TABLE 1 Coronary Artery Measurements
Time Point BSA RCA, mm z Score LCA, mm z Score
Presentation 0.29 2 2.6 2.1 2.2
6-wk follow-up 0.30 1.8 1.9 1.9 1.6
6-mo follow-up 0.33 2 1.6 2 1
BSA, body surface area; LCA, left coronary artery; RCA, right coronary artery.
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Kawasaki disease should receive IVIg
and high-dose aspirin before the 10th
day of fever.13,14
The ﬁnding of dilated coronary arteries
in a febrile child is considered to be
agood indicatorofKawasakisyndrome ,
as recommended by the American
Heart Association and supported by
Bratincsak et al.15,16 A comparison was
made between 145 children with
Kawasaki syndrome and 45 children
with fever (36 with infectious illness
and 9 with a self-limiting febrile con-
dition); they found no children in the
non–Kawasaki syndrome group with
a coronary artery z score of $2.5
and a signiﬁcant difference in overall
z scores between the groups. In our
patient with prolonged fever without
an identiﬁable cause, the suspicion of
incomplete Kawasaki syndrome was
supported by the ﬁnding of mildly di-
lated proximal coronary arteries,
which led to the clinical decision to
treat with IVIg. It is important to note
that coronary artery involvement is not
conﬁned to Kawasaki syndrome but
has been documented in some other
inﬂammatory syndromes, especially
vasculitis (microscopic polyangiitis or
polyarteritis nodosa)17 and systemic
onset juvenile arthritis.18 One can
speculate that the dilated coronaries in
our patient were part of a systemic
inﬂammatory response seen in other
autoinﬂammatory syndromes. To our
knowledge, this is the ﬁrst report of
a patient with MKD and signs of dilation
of the coronary arteries. The patho-
genesis behind these ﬁndings is un-
clear.
Although there is no evidence-based
therapy for MVD, NSAIDs and short
courses of steroids reportedly improve
symptoms. Moreover, case reports
mention that biologic agents, especially
anakinra (interleukin-1 receptor an-
tagonist) and etanercept (tumor ne-
crosis factor-a inhibitor),19,20 can be
beneﬁcial. Alternatively, in a small trial
of adult patients, treatment with sim-
vastatin led to a considerable re-
duction in febrile days compared with
placebo controls.21
The term “hyper-IgD syndrome” was
originally given to this condition be-
cause elevated levels of IgD were ob-
served in patients with periodic fever,
frequently associated with elevated
immunoglobulin A levels in .80% of
cases.5 However, a multicenter, in-
ternational report found that 22% (of
103 patients with HIDS) had normal IgD
levels, although IgD levels tended to
rise as patients grew older.22,23 Indeed,
our patient had normal levels of IgD
(15 mg/L).
CONCLUSIONS
In young infants, incomplete Kawasaki
syndrome can be diagnosed based on
clinical symptomsof feverandcoronary
artery dilation. A ﬁrst episode of sus-
pected Kawasaki syndrome, regardless
of whether it was complete, should be
managed according to existing guide-
lines without delay. However, because
Kawasaki syndrome is a clinical di-
agnosis, and coronary artery dilation
can also be present in some other
systemic inﬂammatory diseases, re-
currence of symptoms after the di-
agnosis of Kawasaki syndrome should
raise the suspicion of MKD or other
autoinﬂammatory syndromes or vas-
culitis (ie, polyarteritis nodosa).
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